" /> Guselkumab - CISMeF





Preferred Label : Guselkumab;

NCIt definition : An orally available, human, immunoglobulin G1 (IgG1) kappa, monoclonal antibody directed against the p19 protein subunit of interleukin-23 (IL-23), with immunomodulating activity. Upon administration, guselkumab binds to the p19 subunit of IL-23, thereby blocking the binding of IL-23 to the IL-23 receptor. This inhibits IL-23-mediated signaling and the differentiation of CD4-positive T-cells into Th1 and Th17 cells. This prevents Th1- and Th17-mediated immune responses and inhibits the production of pro-inflammatory cytokines. This may prevent or reduce symptoms and severity of immune-mediated inflammatory disorders. IL-23 plays a key role in the regulation of inflammation and the immune system, and modulates the release of various pro-inflammatory cytokines and chemokines. It is upregulated in various immune-mediated inflammatory disorders.;

UNII : 089658A12D;

CAS number : 1350289-85-8; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1350289-85-8 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Drug name : Tremfya;

Molecule name : CNTO 1959;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
10/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.